FDA approves Merck's Prevymis for CMV

FDA approved once-daily oral and IV formulations of Prevymis letermovir (MK-8228) from Merck &

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE